Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.
暂无分享,去创建一个
Michael L. Wang | X. Zhang | Sungyoul Hong | Yuhuan Zheng | Siqing Wang | Jing Yang | J. Qian | Z. Cai | Q. Yi | Haiyan S. Li | Xiang Zhang
[1] E. Shpall,et al. Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. , 2006, Blood.
[2] W. Dalton. Drug resistance and drug development in multiple myeloma. , 2002, Seminars in oncology.
[3] Michael L. Wang,et al. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. , 2006, Cancer cell.
[4] R. Kyle,et al. Multiple myeloma. , 2008, Blood.
[5] R. Kyle,et al. Drug therapy: Multiple myeloma , 2004 .
[6] B. Barlogie,et al. Cancer and the Microenvironment , 2004, Cancer Research.
[7] M. Jourdan,et al. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. , 1990, European cytokine network.
[8] Michael L. Wang,et al. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. , 2007, Cancer cell.
[9] P. Allavena,et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.
[10] R. Crystal,et al. Antigen-pulsed dendritic cells expressing macrophage-derived chemokine elicit Th2 responses and promote specific humoral immunity. , 2001, The Journal of clinical investigation.
[11] J. Epstein,et al. Consequences of interactions between the bone marrow stroma and myeloma. , 2003, The hematology journal : the official journal of the European Haematology Association.